Agents with vasodilator properties in acute heart failure: How to design successful trials

European Journal of Heart Failure

Volumn 17, Issue 7, 2015, Pages 652-664

  Mebazaa, Alexandre ^a,b   Longrois, Dan ^c   Metra, Marco ^d   Mueller, Christian ^e   Richards, Arthur Mark ^f,g   Roessig, Lothar ^h   Seronde, Marie France ⁱ   Sato, Naoki ^j   Stockbridge, Norman L ^k   Gattis Stough, Wendy ^l   Alonso, Angeles ^m   Cody, Robert J ⁿ   Cook Bruns, Nancy ^h   Gheorghiade, Mihai ^o   Holzmeister, Johannes ^p   Laribi, Said ^b   Zannad, Faiez ^q  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h BAYER PHARMA AG   (Germany)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l CAMPBELL UNIVERSITY   (United States)

^m EUROPEAN MEDICINES AGENCY   (United Kingdom)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

^p Cardiorentis Ltd   (Switzerland)

^q UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

Acute heart failure; Clinical trials; Vasodilator

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CENDERITIDE; CINACIGUAT; CLEVIDIPINE; CXL 1020; CXL 1427; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; LEVOSIMENDAN; NESIRITIDE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; PLACEBO; ROLOFYLLINE; SERELAXIN; TEZOSENTAN; TRV 120027; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HEART AFTERLOAD; HEART INFARCTION; HEART PRELOAD; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION; HEART FAILURE; PHYSIOLOGY; PROCEDURES;

BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; VASODILATOR AGENTS;

EID: 84947864581     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.294     Document Type: Article

References (99)

1. Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats AJ, Poole-Wilson PA, Sutton GC,. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002; 23: 877-885.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de FS, Despres J, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB,. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-e322.
3. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO,. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61: 391-403.
4. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A,. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011; 37: 619-626.
5. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB,. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007; 167: 1493-1502.
6. Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M, Maggioni AP, Gheorghiade M, Ando Y, Pocock SJ, Zannad F, O'Connor CM,. Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J 2013; 166: 629-635.
7. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F, Pitt B, O'Connor C, Felker GM,. Decongestion in acute heart failure. Eur J Heart Fail 2014; 16: 471-482.
8. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M,. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
9. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM,. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
10. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M,. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
11. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M,. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
12. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A,. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351: 389-393.
13. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt A, Simovitz A, Shaham O, Faigenberg Z, Metzger M, Stav D, Yogev R, Golik A, Krakover R, Vered Z, Cotter G,. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000; 36: 832-837.
14. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T,. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103-111.
15. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC,. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226.
16. Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M,. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 2011; 13: 961-967.
17. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM,. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003.
18. Patel PA, Heizer G, O'Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, Armstrong PW, Hasselblad V, Mills RM, McMurray JJ, Starling RC, Tang WH, Califf RM, Hernandez AF,. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail 2014; 7: 918-925.
19. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
20. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR,. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
21. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS,. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96: 11G-17G.
22. Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G,. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008; 36: S129-S139.
23. Adams KF, Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP,. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
24. Cleland JG, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Follath F, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Preda I, van Gilst WH, Widimsky J, Mareev V, Mason J, Freemantle N, Eastaugh J,. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail 2000; 2: 123-132.
25. Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Guize L, Alla F, Rouge P, Blin P, Barlet MH, Paolozzi L, Vincent C, Desnos M, Samii K,. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 2006; 8: 697-705.
26. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH,. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-596.
27. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A,. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013; 34: 742-749.
28. Guinot PG, Arab OA, Longrois D, Dupont H,. Right ventricular systolic dysfunction and vena cava dilatation precede alteration of renal function in adult patients undergoing cardiac surgery: an observational study. Eur J Anaesthesiol 2014; in press.
29. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G,. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010; 12: 423-433.
30. Colombo PC, Doran AC, Onat D, Wong KY, Ahmad M, Sabbah HN, Demmer RT,. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep 2015; 12: 215-222.
31. Ponikowski P, Jankowska EA,. Pathogenesis and clinical presentation of acute heart failure. Rev Esp Cardiol (Engl Ed) 2015; 68: 331-337.
32. Laurent S, Cockcroft J, Van BL, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H,. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
33. Safar ME, Levy BI, Struijker-Boudier H,. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864-2869.
34. Pang CC,. Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 2001; 90: 179-230.
35. Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M,. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014; 35: 431-441.
36. Allen LA, Rogers JG, Warnica JW, DiSalvo TG, Tasissa G, Binanay C, O'Connor CM, Califf RM, Leier CV, Shah MR, Stevenson LW,. High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail 2008; 14: 661-669.
37. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I,. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-2019.
38. VMAC Investigators,. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540.
39. Piper S, McDonagh T,. The role of intravenous vasodilators in acute heart failure management. Eur J Heart Fail 2014; 16: 827-834.
40. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, Asai K, Murai K, Muanakata R, Aokage T, Sakata Y, Mizuno K, Takano T,. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944-951.
41. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L,. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736.
42. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M,. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133.
43. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
44. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, Salter N, Fermann GJ, Pospisil C,. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013; 8:CD005151.
45. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH,. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008; 52: 200-207.
46. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM,. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14: 631-640.
47. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC,. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50: 1551-1560.
48. Violin JD, Soergel DG, Boerrigter G, Burnett JC, Jr., Lark MW,. GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc Med 2013; 23: 242-249.
49. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E,. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995; 116: 1589-1594.
50. Jeyabalan A, Shroff SG, Novak J, Conrad KP,. The vascular actions of relaxin. Adv Exp Med Biol 2007; 612: 65-87.
51. Jelinic M, Leo CH, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME, Conrad KP, Parkington H, Tare M, Parry LJ,. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 2014; 28: 275-287.
52. Fedele F, Bruno N, Brasolin B, Caira C, D'Ambrosi A, Mancone M,. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail 2014; 16: 281-288.
53. Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F,. Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. Mol Pharm 2014; 11: 4374-4384.
54. Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, Alvarez D, Jarvinen TA, Mann D, Ruoslahti E, McMurtry IF, Oka M,. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. Am J Pathol 2014; 184: 369-375.
55. Guarracino F, Cariello C, Danella A, Doroni L, Lapolla F, Stefani M, Baldassarri R, Vullo C,. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand 2007; 51: 1217-1224.
56. Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS,. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756-1763.
57. Popovic ZB, Khot UN, Novaro GM, Casas F, Greenberg NL, Garcia MJ, Francis GS, Thomas JD,. Effects of sodium nitroprusside in aortic stenosis associated with severe heart failure: pressure-volume loop analysis using a numerical model. Am J Physiol Heart Circ Physiol 2005; 288: H416-H423.
58. Pagnamenta A, Dewachter C, McEntee K, Fesler P, Brimioulle S, Naeije R,. Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure. J Appl Physiol (1985) 2010; 109: 1080-1085.
59. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A,. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343-2348.
60. Breidthardt T, Noveanu M, Potocki M, Reichlin T, Egli P, Hartwiger S, Socrates T, Gayat E, Christ M, Mebazaa A, Mueller C,. Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. J Intern Med 2010; 267: 322-330.
61. Singh A, Laribi S, Teerlink JR, Mebazaa A,. Agents with vasodilator properties in acute heart failure. Eur Heart J 2015; in press.
62. O'Connor CM, Gattis WA, Adams KF, Jr., Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M,. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003; 41: 1452-1457.
63. Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H,. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306: 1129-1135.
64. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H,. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-684.
65. Peacock WF, Chandra A, Char D, Collins S, Der Sahakian G, Ding L, Dunbar L, Fermann G, Fonarow GC, Garrison N, Hu MY, Jourdain P, Laribi S, Levy P, Mockel M, Mueller C, Ray P, Singer A, Ventura H, Weiss M, Mebazaa A,. Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-a Pilot Study (PRONTO). Am Heart J 2014; 167: 529-536.
66. Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H, Cotter G,. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009; 14: 299-307.
67. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure (TRUE-AHF). http://www.clinicaltrials.gov/ct2/show/NCT01661634 (19 November 2014).
68. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM,. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009; 157: 271-277.
69. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I,. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005; 150: 46-53.
70. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T,. Effect of levosimendan on the short-term-clinical course of patients with acutely-decompensated heart failure. JACC: Heart Failure 2013; 1: 103-111.
71. Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in AHF. http://www.clinicaltrials.gov/ct2/show/NCT01870778 (17 January 2014).
72. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA,. Design of the RELAXin in acute heart failure study. Am Heart J 2012; 163: 149-155.
73. Colombo PC, Rastogi S, Onat D, Zaca V, Gupta RC, Jorde UP, Sabbah HN,. Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail 2009; 15: 457-463.
74. Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, LeJemtel TH, Bucciarelli L, Kebschull M, Papapanou P, Uriel N, Schmidt AM, Sabbah HN, Jorde UP,. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J 2014; 35: 448-454.
75. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Court, Hasa J, Spinar J, Masip J, Frank PW, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M,. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010; 31: 832-841.
76. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ,. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013; 15: 1082-1094.
77. Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M,. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF Study. J Am Coll Cardiol 2014; 64: 1591-1598.
78. Allen LA, Hernandez AF, O'Connor CM, Felker GM,. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 2248-2258.
79. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M,. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010; 3: 314-325.
80. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Pina IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N,. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009; 157: 957-970.
81. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, DiMarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC,. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-389.
82. Zamani P, Greenberg BH,. Novel vasodilators in heart failure. Curr Heart Fail Rep 2013; 10: 1-11.
83. Goal-directed afterload reduction in acute congestive cardiac decompensation study (GALACTIC). http://clinicaltrials.gov/ct2/show/NCT00512759?term=NCT00512759&rank=1 (19 November 2014).
84. Maron B, Rocco T,. Pharmacotherapy of congestive heart failure. In:, Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011.
85. Ezekowitz JA,. Novel pharmacologic therapies in development for acute decompensated heart failure. Curr Cardiol Rep 2013; 15: 329.
86. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M,. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823-2832.
87. Tavares M, Rezlan E, Vostroknoutova I, Khouadja H, Mebazaa A,. New pharmacologic therapies for acute heart failure. Crit Care Med 2008; 36: S112-S120.
88. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ,. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010; 7: 48-58.
89. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G,. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009; 14: 321-329.
90. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M,. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010; 7: 75-82.
91. Rekowski MvW, Kumar V, Zhou Z, Moschner J, Marazioti A, Bantzi M, Spyroulias GA, van den Akker F, Giannis A, Papapetropoulos A. Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics. J Med Chem 2013; 56: 8948-8952.
92. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP,. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-768.
93. Levy PD, Laribi S, Mebazaa A,. Vasodilators in acute heart failure: review of the latest studies. Curr Emerg Hosp Med Rep 2014; 2: 126-132.
94. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr,. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type 1 receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 2012; 5: 627-634.
95. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr,. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011; 4: 770-778.
96. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr., CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One 2012; 7:e52422.
97. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A,. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012; 14: 1056-1066.
98. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC,. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-1428.
99. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M,. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823-2832.